3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 1
3
Phase EARLY_PHASE1
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Uterine Cervical Neoplasms
1
Interventions
Carboplatin
66
Paclitaxel
54
pembrolizumab
49
Cyclophosphamide
34
Cisplatin
28
Bevacizumab
26
Nivolumab
21
Gemcitabine
18
fludarabine
17
liposomal doxorubicin
15
Topotecan
15
aldesleukin
13
Filgrastim
12
olaparib
11
Interleukin-2
11
Docetaxel
11
Peripheral Blood Stem Cell Transplantation
10
durvalumab
9
Taxes
9
Specimen Handling
9
Oxaliplatin
8
fludarabine phosphate
7
epacadostat
7
Magnetic Resonance Spectroscopy
7
Ipilimumab
7
Injections
7
rucaparib
6
niraparib
6
lenvatinib
6
cemiplimab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
adavosertib
×
Gynecologic
×
Clear all
NCT01076400
2023-09-18
MK-1775-008
Merck Sharp & Dohme LLC
Phase 1/2
Terminated
7 enrolled
6 charts